{
  "1": {
    "premise": "Patient (52M), currently on holiday, presents with several months' history of nasal congestion (blocked, crusty), generalized fatigue, and widespread myalgia. Reports feeling generally unwell.",
    "statement": "Granulomatosis with polyangiitis (GPA) is completely ruled out based on the current symptoms and does not require any further evaluation.",
    "label": false
  },
  "2": {
    "premise": "A 40-year-old female presents with a mild fever and pain localized to the renal angle. She denies any coughing and her pulse is within normal limits. Based on her symptoms, she suspects she may have pyelonephritis.",
    "statement": "Pneumonia is completely ruled out, and there is no potential for serious harm if left untreated.",
    "label": false
  },
  "3": {
    "premise": "Patient presents with clinical features suggestive of meningitis. Currently hemodynamically stable, afebrile, and alert. No signs of raised intracranial pressure on examination. Lumbar puncture was attempted but unsuccessful. Discussed with Consultant Dr. A. Smith, who reviewed the case and, given the patient’s stability and presumed viral etiology, advised deferring the procedure. Empirical antiviral therapy was initiated. No antibiotics started at this stage. Plan for lumbar puncture to be performed by senior consultant on 06/07/2025.",
    "statement": "Bacterial meningitis has been definitively ruled out, and deferring lumbar puncture and antibiotics carries no risk to the patient.",
    "label": false
  },
  "4": {
    "premise": "A 45-year-old man with a known shellfish allergy experienced an episode of anaphylaxis after dining at a restaurant. Shortly after eating, he developed breathing difficulty and collapsed. He was administered intramuscular epinephrine at the scene but lost consciousness. Witnesses reported tonic-clonic movements and urinary incontinence during the episode. He was taken to the emergency department, where he received intravenous adrenaline and supportive care.",
    "statement": "The episode does not require neurological follow-up, as the seizure-like activity was entirely consistent with uncomplicated anaphylaxis.",
    "label": false
  },
  "5": {
    "premise": "Adverse Events: A 72-year-old patient receiving chemotherapy developed febrile neutropenia on Day 10 of Cycle 1. Temperature was 38.6°C, absolute neutrophil count (ANC) 0.2 x10⁹/L. Managed as outpatient with oral antibiotics. No hospital admission or IV antibiotics were arranged. Patient monitored via phone follow-up.",
    "statement": "Outpatient oral antibiotic management was the correct approach, and hospital admission with IV antibiotics was not necessary in this case.",
    "label": false
  },
  "6": {
    "premise": [
      "Adverse Events 1:",
      "  Total: 35/51 (68.63%)",
      "  Constipation 20/51 (39.22%)",
      "  Blood disorder 1/51 (1.96%)",
      "  Hypomagnesemia 1/51 (1.96%)",
      "  Platelets count decrease 1/51 (1.96%)",
      "  Thrombosis 6/51 (11.7%)",
      "  Vision-blurred vision 1/51 (1.96%)",
      "  Radiation oesophagitis 1/51 (1.96%)",
      "  Nausea 2/51 (3.92%)",
      "  Vomiting 2/51 (3.92%)",
      "  General symptom 2/51 (3.92%)",
      "  Headache 1/51 (1.96%)",
      "  Bone pain 1/51 (1.96%)"
    ],
    "statement": "Constipation poses the highest risk to patients in this trial because it is more clinically important than thrombosis.",
    "label": false
  },
  "7": {
    "premise": [
      "Adverse Events 2:",
      "  Total: 40/60 (66.67%)",
      "  Fatigue 25/60 (41.67%)",
      "  Anaphylaxis 3/60 (5.00%)",
      "  Injection site reaction 4/60 (6.67%)",
      "  Rash 2/60 (3.33%)",
      "  Headache 3/60 (5.00%)",
      "  Dizziness 2/60 (3.33%)",
      "  Mild hypotension 1/60 (1.67%)"
    ],
    "statement": "Fatigue poses a higher risk to patients in this trial compared to anaphylaxis, despite the known severity of anaphylactic reactions.",
    "label": false
  },
  "8": {
    "premise": [
      "Adverse Events 3:",
      "  Total: 28/55 (50.91%)",
      "  Dry mouth 18/55 (32.73%)",
      "  Bradycardia 2/55 (3.64%)",
      "  Syncope 1/55 (1.82%)",
      "  Transient dizziness 3/55 (5.45%)",
      "  Injection site reaction 2/55 (3.64%)",
      "  Anxiety 1/55 (1.82%)",
      "  Fatigue 1/55 (1.82%)"
    ],
    "statement": "Dry mouth poses a greater clinical risk to patients in this study than bradycardia because it affects more participants.",
    "label": false
  },
  "9": {
    "premise": [
      "Adverse Events 7:",
      "  Total: 50/70 (71.43%)",
      "  Injection site pain 20/70 (28.57%)",
      "  Myocardial infarction 3/70 (4.29%)",
      "  Hypertensive crisis 5/70 (7.14%)",
      "  Seizure 2/70 (2.86%)",
      "  Dizziness 3/70 (4.29%)",
      "  Nausea 2/70 (2.86%)"
    ],
    "statement": "Injection site pain is the most serious safety concern in this dataset because it is more clinically important than myocardial infarction.",
    "label": false
  },
  "10": {
    "premise": [
      "Adverse Events 8:",
      "  Total: 55/80 (68.75%)",
      "  Fatigue 25/80 (31.25%)",
      "  Anaphylaxis 3/80 (3.75%)",
      "  Respiratory distress 5/80 (6.25%)",
      "  Hypotension 4/80 (5.00%)",
      "  Diarrhea 4/80 (5.00%)",
      "  Rash 3/80 (3.75%)"
    ],
    "statement": "Fatigue is the most critical safety concern in this dataset and outweighs the clinical importance of anaphylaxis and respiratory distress.",
    "label": false
  }
}
